Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Tatsuya Atsumi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Objective
This study evaluated the effectiveness and cost-effectiveness of baricitinib, tofacitinib, and upadacitinib regimens, compared to conventional synthetic disease-modifying antirheumatic drug (csDMARD) alone, among Japanese patients with moderate-to-severe rheumatoid arthritis (RA) inadequately responsive to csDMARD, measured in terms of number needed to treat (NNT) and cost per responder (CPR).
Methods
Efficacy data were derived from two recent network meta-analyses among global and Japanese population. The cost perspective was that of the Japanese Health Service. Both NNT and CPR were based on disease activity score for 28 joints with C-reactive protein (DAS28-CRP) remission and American College of Rheumatology (ACR) 20/50/70 at 12 and 24 weeks.
Results
Over 12 weeks, the median NNT and the median CPR to achieve DAS28-CRP remission were 4.3 and JPY 1,799,696 [USD 16,361], respectively, for upadacitinib 15 mg + csDMARD. The equivalent results were 6.0 and JPY 2,691,684 [USD 24,470] for baricitinib 4 mg + csDMARD and 5.6 and JPY 2,507,152 [USD 22,792] for tofacitinib 5 mg + csDMARD. Similar rankings were observed at 24 weeks and for other outcomes.
Conclusions
Upadacitinib 15 mg was associated with the lowest NNT and CPR among the three Janus kinase inhibitors used in treatment regimens for Japanese patients with moderate-to-severe RA inadequately responsive to csDMARD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
- AbbVie GK, Tokyo, Japan.
- AbbVie Inc., North Chicago, IL, USA.
ORCID-Profile: Isao Kawaguchi
Förderung
- AbbVie
Zitieren
APA
Atsumi, T., Asakura, E., Doi, M., Sawant, R., Kawaguchi, I., Sasaki, N., & Liew, D. (2023). Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan. Modern Rheumatology. https://doi.org/10.1093/mr/roac015
Vancouver
Atsumi T, Asakura E, Doi M, Sawant R, Kawaguchi I, Sasaki N, et al. Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan. Modern Rheumatology. 2023. doi:10.1093/mr/roac015
BibTeX
@article{Atsumi2023,
author = {Atsumi, Tatsuya and Asakura, Eri and Doi, Michio and Sawant, Ruta and Kawaguchi, Isao and Sasaki, Nobuhito and Liew, Danny},
title = {Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac015}
}
EUVIMED